Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mineralized dentin is the calcified tissue that forms the bulk of the tooth, providing structural integrity and protecting the underlying dental pulp (StatPearls, 2023). It is composed of approximately 70% inorganic hydroxyapatite, 20% organic material (predominantly Type I collagen), and 10% water (PubMed, PMID: 27507480). The tissue is characterized by the presence of dentinal tubules, which extend from the pulp to the dentino-enamel junction and play a vital role in tooth sensitivity and fluid transport (NIH, 2022). In clinical dentistry, mineralized dentin is a primary target for remineralization therapies using fluoride or calcium-based agents to combat dental caries (Journal of Dental Research, 2018). It also serves as the substrate for adhesive restorations, where the stability of the collagen-resin interface is essential for long-term durability (PubMed, PMID: 22266128). Furthermore, treatments for dentin hypersensitivity target the tubules within the mineralized matrix to block external stimuli from reaching the pulpal nerves (Cochrane Database, 2020). The degradation of the organic matrix by endogenous enzymes like matrix metalloproteinases is a major challenge in restorative dentistry, leading to the failure of dentin bonds (PubMed, PMID: 23407137). Therapeutic interventions often aim to either reinforce this mineralized structure or seal its porous surface to maintain oral health.
The primary mechanisms of action for drugs targeting mineralized dentin include remineralization through the formation of fluorapatite, which is more acid-resistant than hydroxyapatite (PubChem); the physical occlusion of dentinal tubules to reduce hydrodynamic fluid movement and subsequent nerve activation (StatPearls); and the inhibition of endogenous matrix metalloproteinases (MMPs) and cysteine cathepsins to prevent the enzymatic degradation of the collagen matrix (PubMed, PMID: 23407137).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mineralized dentin.